title: Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation.
abstract: The effect of oral finasteride, an inhibitor of 5alpha-reductase, on the clearance of tirilazad, a membrane lipid peroxidation inhibitor, was assessed in eight healthy men who received: 1) 10 mg/kg tirilazad mesylate solution orally on the 7th day of a 10-day regimen of 5 mg finasteride once daily, 2) 10 mg/kg tirilazad mesylate orally, 3) 2 mg/kg tirilazad mesylate i.v. on the 7th day of a 10-day regimen of 5 mg finasteride once daily and 4) 2 mg/kg tirilazad mesylate i.v., in a four-way cross-over design. Plasma concentrations of tirilazad and its active reduced metabolites (U-89678 and U-87999) were measured by liquid chromatography with tandem mass spectrometry (LC-MS-MS). Finasteride increased mean tirilazad areas under the curve by 21 and 29% for i.v. and p.o. tirilazad, respectively. Mean U-89678 areas under the curve were decreased 92 and 75% by finasteride administration with i.v. and p.o. tirilazad, respectively, and decreases of 94 and 85% in mean U-87999 area under the curve values were observed. These differences were statistically significant. These results indicate that finasteride inhibits the metabolism of tirilazad to U-89678. However, this inhibition has only a moderate effect on the overall clearance of tirilazad. These results thus confirm earlier in vitro work that showed that tirilazad is predominantly metabolized by CYP3A4. Although the major circulating metabolites of tirilazad are formed via reduction, this represents a minor route of tirilazad elimination in man.
authors.affiliation: Clinical Pharmacokinetics, Pharmacia and Upjohn, Inc., Kalamazoo, Michigan, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Fleishaker
authors.forename: P G
authors.initials: PG
authors.lastname: Pearson
authors.forename: L C
authors.initials: LC
authors.lastname: Wienkers
authors.forename: L K
authors.initials: LK
authors.lastname: Pearson
authors.forename: T A
authors.initials: TA
authors.lastname: Moore
authors.forename: G R
authors.initials: GR
authors.lastname: Peters
mesh_terms: D000293:Adolescent; D000328:Adult; D019540:Area Under Curve; D001711:Biotransformation; D042944:Cholestenone 5 alpha-Reductase; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D018120:Finasteride / Q000494:pharmacology*; D016166:Free Radical Scavengers / Q000494:pharmacology; D006207:Half-Life; D006801:Humans; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D011281:Pregnatrienes / Q000493:pharmacokinetics*; D012016:Reference Values
chemical_list: D004791:Enzyme Inhibitors; D016166:Free Radical Scavengers; D018696:Neuroprotective Agents; D011281:Pregnatrienes; D018120:Finasteride; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase; C053355:tirilazad